Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
NCT06334731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2025-07-28
Summary
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Conditions
Sponsors & Collaborators
-
Methodist Health System
lead OTHER
Principal Investigators
-
Mathew Crotty, PharmD · The Methodist Hospital Research Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-06
- Primary Completion
- 2025-07-14
- Completion
- 2025-07-14
Countries
- United States
Study Locations
More Related Trials
-
Antimicrobial Drug Use and Resistant Staphylococcus Aureus
NCT01075451 ·Status: COMPLETED
-
Microbiological Characterization and Nasal Carriage Rates of Methicillin Resistant Staphylococcus Aureus (MRSA) in Vancouver Downtown Eastside
NCT00247871 ·Status: COMPLETED
-
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
NCT04332094 ·Status: UNKNOWN ·Phase: PHASE2
-
AMR-DetecTool for the Diagnostic of MDR Bacterial Infections
NCT05378217 ·Status: COMPLETED
-
Case Fatalities in Hospitalised COVID-19 Patients in the UK
NCT04527458 ·Status: COMPLETED
-
Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2
NCT04611841 ·Status: UNKNOWN
-
COVID-19 Vaccination AZV 2021-2023
NCT05589233 ·Status: COMPLETED
-
MDR Bacilli Surveillance and Clinical Feature in China
NCT02140853 ·Status: UNKNOWN
-
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
NCT05256316 ·Status: COMPLETED
-
Evaluation of Antibody Tests for COVID-19
NCT04360954 ·Status: COMPLETED
-
COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2
NCT04318314 ·Status: UNKNOWN
-
Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
NCT04934215 ·Status: COMPLETED
-
Surveillance of AMR in DRC
NCT06821282 ·Status: RECRUITING
-
Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
NCT05244330 ·Status: COMPLETED
-
Feasibility and Usability of COVID-19 Antigen RDTs in Uganda
NCT05630300 ·Status: COMPLETED ·Phase: NA
-
Antimicrobial Resistance in Hospitals From Meta, Colombia
NCT06044272 ·Status: COMPLETED
-
Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
NCT04523831 ·Status: COMPLETED ·Phase: PHASE3
-
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
NCT05020145 ·Status: COMPLETED
-
Factors Impacting the Prevalence of MDR Bacteria
NCT05100407 ·Status: COMPLETED
-
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
NCT06392451 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031 ·Status: NOT_YET_RECRUITING
-
TOcilizumab and Covid-19 : Risk of Severe INfection
NCT05017441 ·Status: UNKNOWN
-
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
NCT04339426 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
NCT04597242 ·Status: NO_LONGER_AVAILABLE
-
Network on Antimicrobial Resistance in Staphylococcus Aureus
NCT00341913 ·Status: COMPLETED